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Arsenic trioxideSnoN/SkiL (TGFb regulator) is dysregulated in ovarian cancer, a disease associated with acquired
drug-resistance. Arsenic trioxide (As2O3, used in treating APL) induces SnoN to oppose the apoptotic
response in ovarian cancer cells. We now report that As2O3 increases phosphorylation of EGFR/
p66ShcA and EGFR degradation. As2O3 activates Src(Y416) whose activity (inhibited by PP2) modu-
lates EGFR activation, its interaction with Shc/Grb2, and p-AKT. Inhibition of PI3K reduces SnoN and
cell survival. Although EGFR or MAPK1 siRNA did not alter SnoN expression, As2O3-induced cleaved
PARP was reduced together with increased XIAP. Collectively, As2O3 mediates an initial rise in pY-
Src(416) to regulate the PI3K/AKT pathway which increases SnoN and cell survival; these early
events may counter the cell death response associated with increased pY-EGFR/MAPK activation.
Structured summary of protein interactions:
ShcA physically interacts with GRB2 by anti bait coimmunoprecipitation (View interaction)
EGFR physically interacts with ShcA by anti bait coimmunoprecipitation (View interaction)
EGFR physically interacts with GRB2 and ShcA by anti bait coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction located at the 3q26.3 locus [3]. Inhibition of this pathway sensitizesOvarian cancer is one of the leading causes of cancer deaths
amongwomen in theUnited States. Regrettably, the current chemo-
therapeutics (platinum/taxane-based drugs) have not markedly in-
creased recurrence-free survival of this deadlydisease. Thus, there is
an urgent need for the development of novel treatment strategies.
Speciﬁc genes located in regions of genomic aberrations associated
with ovarian cancers include two co-transcriptional repressors,
SnoN/SkiL [1] and ecotropic viral integration site-1 (EVI1) [2],
ampliﬁed at the 3q26.2 locus and involved in the TGFb signaling
cascade. Other genetic alterations include ampliﬁcation of the
catalytic subunit of phosphatidylinositol 3-kinase (PI3K, PIK3CA)multiple cancer cell types to chemotherapeutic agents [4].
As2O3, a clinically approved drug in the treatment of acute pro-
myelocytic leukemia (APL), elicits antitumor properties in cells de-
rived from solid tumors such as ovarian cancers [5]. As2O3
treatment leads to cytotoxicity via induction of apoptosis [5]. We
have shown that As2O3 treatment in epithelial ovarian cancer cells
alters expression of certain TGFb mediators [6]. This cytotoxic
agent markedly induces SnoN/SkiL expression concurrent with
pro-survival autophagy in a reactive oxygen species (ROS) depen-
dent manner. This protective pathway antagonizes the As2O3-in-
duced apoptotic response [6]. Indeed, small interfering RNA-
mediated SnoN knockdown increases the sensitivity of ovarian
cancer cells to As2O3 [6]. However, the mechanisms through which
As2O3 induce SnoN expression and the consequent cell death re-
sponse are not clearly understood.
Herein, we assess the contribution of EGFR and downstream
pathways including activation of the Src/PI3K/AKT and ShcA/
Grb2/MAPK signaling pathways to As2O3-induced SnoN expression
and the cell death response. We identiﬁed that As2O3 activates
EGFR and promotes phosphorylation of p66 ShcA and its interac-
tion with the Grb2 adaptor protein with slower kinetics compared
to EGF-mediated EGFR activation. Furthermore, EGFR is degraded
upon As2O3 treatment in combination with cycloheximide.
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GDC0941 (to a lesser degree)), and knockdown of PIK3CA altered
As2O3-induced changes in SnoN expression. In contrast to EGF,
PP2 modulated As2O3-induced EGFR activation and interaction
with Shc/Grb2. We also noted reduced Grb2–EGFR interaction with
p66 ShcA knockdown in the presence of As2O3 implicating p66
ShcA isoform in mediating this interaction. With MAPK1 and EGFR
(to a lesser extent) siRNA, we noted a signiﬁcant increase in cell
survival. Together, our results implicate activation of the pro-sur-
vival PI3K pathway in As2O3-induced changes in SnoN expression
and cell survival. These events occur prior to full activation of the
EGFR/MAPK pathway which may contribute to the As2O3-induced
cell death response.
2. Materials and methods
2.1. Cell culture
HEY ovarian carcinoma cells were kindly provided by Dr. Gor-
don Mills (MD Anderson Cancer Center, TX) and cultured in RPMI
1640 supplemented with 8% FBS and penicillin/streptomycin. Cells
were maintained in a 37 C humidiﬁed incubator containing 95%
air and 5% CO2.
2.2. Cell treatments with EGF, As2O3, and signaling pathway inhibitors
EGF, SU6656, and PP2 were obtained from Calbiochem (Rock-
land, MA). As2O3 was obtained from Sigma–Aldrich (St. Louis,
MO). U0126 and LY294002 were obtained from Cell Signaling
Technology (Danvers, MA). PD153035 was obtained from A.G. Sci-
entiﬁc (San Diego, CA). GDC0941 was obtained from Selleckchem
(Houston, TX). Actinomycin D was obtained from MP Biomedicals
(Solon, OH). PP2, U0126, PD153035, LY294002, SU6656, and
GDC0941 were dissolved in dimethylsulfoxide (DMSO). Cells were
pretreated with PP2, U0126, and PD153035 for 2 h prior to treat-
ment with either EGF or As2O3. All other inhibitors were added
concurrently with EGF or As2O3.
2.3. siRNA treatment of ovarian carcinoma cell lines
siRNA targeting EGFR (L-003114-00), pp60 c-Src (L-003175-00),
MAPK1 (L-003555-00), PIK3CA (L-003018-00), non-targeting ON-
TARGETPlus control siRNA (D-001810-10), and Dharmafect I trans-
fection reagent were obtained from Dharmacon (Lafayette, CO).
ShcA p66 siRNA was custom designed (obtained from Dharmacon)
based on a published sequence towards its CH2 domain [7]. The
sense sequence is 50-GAAUGAGUCUCUGUCAUCGUU-30 and anti-
sense sequence is 50-CGAUGACAGAGACUCAUUCUU-30. The siRNA
transfection method was followed according to our previously
published studies [6]. Mock transfection was performed in the ab-
sence of siRNA, as control.
2.4. Protein isolation and immunoprecipitation (IP)
Cells were lysed in lysis buffer (1% Triton X-100, 50 mM HEPES,
150 mMNaCl, 1 mMMgCl2, 1 mM EGTA, 10% glycerol, and protease
inhibitor cocktail (Roche, Madison, WI)) for 1 h at 4 C. Cells lysates
were harvested and centrifuged at 14000 rpm for 10 min at 4 C.
An aliquot of the supernatant was collected for analysis (inputs).
Quantiﬁcation of total protein was performed using the Bicinchon-
inic Acid assay (Fisher Scientiﬁc, Pittsburgh, PA) and then the sam-
ples were normalized to a minimum concentration of 1 mg/ml. For
IP, 5 ll of anti-EGFR (200 lg/ml of EGFR rabbit polyclonal) or anti-
Shc (250 lg/ml) antibody was added to the cell lysates and incu-
bated on a shaking platform for 3 h at 4 C. This was followed bythe addition of 40 ll of Protein G Sepharose 4 Fast Flow Beads
(Amersham Biosciences, Piscataway, NJ) followed by a further 1 h
incubation at 4 C. The immunoprecipitates were sedimented and
washed extensively with lysis buffer as well as PBS. Proteins were
eluted from the beads by heating to 95 C with 5% SDS sample
buffer.
2.5. SDS–PAGE and Western blot analyses
Protein samples were analyzed on appropriate percentage (8%,
10%, or 12%) SDS–PAGE gels and transferred to polyvinylidene ﬂuo-
ride (PVDF) membranes and used for Western blotting according to
previously published methods [6]. Bound antibody was detected
using enhanced chemiluminescence reagent (Bio-Rad, Hercules,
CA) followed by exposure to ﬁlm.
Primary antibodies were used at the following dilutions. PY99
(HRP conjugated, SC-7020, 1:1000), SnoN rabbit polyclonal (SC-
914, 1:1000), and EGFR rabbit polyclonal (SC-03, 1:1000) antibod-
ies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
PARP rabbit polyclonal (#9542, 1:1000), p-AKT (Ser473) rabbit
polyclonal (#4060, 1:1000), AKT rabbit polyclonal (#4685,
1:1000), PIK3CA rabbit polyclonal (#4249, 1:1000), p-Src (416)
rabbit monoclonal (#2113, 1:1000), c-Src mouse monoclonal
(#2110, 1:1000), XIAP rabbit monoclonal (#2045, 1:1000), Bcl-XL
rabbit monoclonal (#2764, 1:1000), and GAPDH rabbit polyclonal
(#2118, 1:4000 dilution) antibodies were obtained from Cell Sig-
naling Technology (Danvers, MA). Shc rabbit polyclonal (#06-
203, 1:1000) antibody was obtained from Millipore (Billerica,
MA). Grb2 mouse monoclonal (#610111, 1:2000) antibody was ob-
tained from BD Biosciences (San Jose, CA). pSer–p66Shc mouse
monoclonal antibody (#566807, 1:1000) was obtained from Cal-
biochem (Rockland, MA).
2.6. Quantitative PCR
Total RNA was isolated from HEY cells using the RNeasy Mini kit
(Qiagen, Valencia, CA). Quantitative PCR was performed using One-
Step PCR Taqmanmaster mix, primers/probes for SnoN (Assays-by-
Design, Hs00180524_m1), and One-Step-Plus Detection System
(Applied Biosystems, Bedford, MA) using b-actin as endogenous
control. PCR conditions and analyses were followed according to
previously published methods [6].
2.7. Apoptosis assays
Using the kit obtained from Calbiochem (Rockland, MA), assays
were performed as previously published [6]. Samples were ana-
lyzed by ﬂow cytometry (College of Medicine, University of South
Florida). Signals were detected at 518 nm for FL1 and at 620 nm for
FL2, respectively.
2.8. Caspase assays
Caspase Glo-3/7 activity assays (Promega, Madison, WI) were
performed according to the manufacturer’s instructions. Brieﬂy,
50000 cells were seeded per well in an opaque 96-well plate and
appropriate drug treatments were then performed, followed by
the addition of 100 ll of caspase activity substrate. Luminescence
readings were measured using a BioTek plate reader.
2.9. Phosphatase assays
Phosphatase assay was performed using the 1-Step PNPP as
substrate which was obtained from ThermoScientiﬁc. To cell
lysates, 100 ll of 1-Step PNPP was added and mixed. The reaction
was incubated at room temperature for 30 min followed by
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bance was measured at 405 nm.
2.10. Statistical analyses
The number of replicates conducted for each experiment is indi-
cated in the ﬁgure legends. Error bars displayed on the bar graphs
represent standard deviations. Data represented in tabular format
(Figs. 3K and 4B) are displayed as averages ± standard deviations.
Western blots were analyzed by densitometric analyses using Im-
age J program (Image Processing and Analysis in Java, NIH Image
Software, http://rsb/info/nioh/gov.ij/) as previously described [6].
P-values were calculated based on the Student’s t-test (P-value
<0.05, ⁄; P-value <0.001, ⁄⁄).
3. Results
3.1. As2O3 induces EGFR and ShcA phosphorylation and interaction
with Grb2 adaptor proteins in HEY ovarian carcinoma cells
To assess whether HEY cells undergo EGFR activation in re-
sponse to As2O3, we treated HEY cells with 5, 10, or 25 lM As2O3
(doses previously reported [6]) and contrasted their cellular re-
sponses to EGF-treated cells (Fig. 1A). Following 1 h EGF, we ob-
served a marked increase in pY-EGFR, reduced mobility of ShcA
isoforms, and activation of AKT (Ser473). EGFR levels appear to dis-
appear rapidly upon 1 h treatment when it becomes heavily phos-
phorylated; this may be due to the antibody detecting
unphosphorylated form of EGFR compared to total EGFR or to
receptor internalization which is not extracted or detected under
our conditions. Protein levels of ShcA and Grb2 decreased rapidly
at 6 h EGF. The results with the three doses of As2O3 were similar
although with increased intensity with elevated doses. In contrast,
As2O3 induced pY-EGFR with slower kinetics peaking at 18 h post
stimulation and expression of ShcA/Grb2 decreased gradually until
30 h (Fig. 1B). Similar to EGF, p-AKT occurred 1 h post As2O3 treat-
ment followed by a rapid decay. Subsequent to p-AKT activation,
SnoN increased at 6 h followed by a rapid decay with As2O3. In con-
trast, there were no reproducible changes in SnoN with EGF. We
have assessed phospho-Src (Y416) which shows a biphasic proﬁle
(initial rise at 1–6 h and second increase at 18 h). At least 10 lM
As2O3 is needed in HEY cells to observe cleaved PARP with a signif-
icant apoptotic response (Fig. 1B and C). In addition, the expression
levels of anti-apoptotic markers (Bcl-XL and XIAP) were markedly
reduced with As2O3 treatment. Thus, upon cellular treatment with
As2O3, the kinetics of EGFR phosphorylation and downstream con-
sequences on ShcA/Grb2 and SnoN expression suggest a different
mechanism of EGFR and downstream signaling pathway activation
in contrast to EGF.
To determine whether altered phosphatase activity could lead
to the increased pY-EGFR with As2O3 as previously reported to oc-
cur with arsenite treatment [8], we measured phosphatase activity
using PNPP as substrate between 1 and 30 h As2O3 across all doses
(5, 10, and 25 lM) (results not shown). However, no changes in
phosphatase activity were observed suggesting that other mecha-
nisms are responsible for As2O3-mediated changes in pY-EGFR.
Similar to EGF treatment which is well-established to lead to EGFR
degradation in lysosomes following ubiquitination, we have noted
that co-treatment of cells with As2O3 (10 and 25 lM) and cyclo-
heximide, an inhibitor of protein translation, did not alter reduc-
tion in EGFR levels (Fig. 1D) suggesting that EGFR is degraded
upon As2O3 treatment in HEY cells.
We next determined whether there was increased interaction of
adaptor molecules (ShcA and Grb2) upon As2O3-induced activation
of EGFR. Similar to EGF, immunoprecipitated pY-EGFR associatedwith p66 ShcA in both the absence and presence of As2O3 treat-
ment. Since the p46/52 ShcA isoforms co-migrated with IgG, we
could not assess their phosphorylation status or kinetics of interac-
tion with EGFR. However, we observed increased Grb2 binding to
pY-EGFR (for both EGF and As2O3) (Fig. 1F and G). The mobility
of p66 ShcA was reduced at 6 h As2O3 treatment suggestive of a
phosphorylation event; indeed, p66 ShcA was positive for pSer36
(Fig. 1G). Longer incubation (9 and 18 h) times (Fig. 1H) leads to in-
creased phosphorylation of p66 Shc with 10 and 25 lM As2O3. Col-
lectively, these results indicate that As2O3 induces increased
interaction of Grb2 with pY-EGFR/Shc complex whose kinetics
and phosphorylation pattern differ markedly to that of EGF.
3.2. Src tyrosine kinase inhibitor, PP2 but not SU6656, alters As2O3-
induced EGFR activation, its interaction with ShcA/Grb2 adaptor
proteins, and SnoN expression
To identify the signaling pathways that are responsible for
As2O3-induced changes in SnoN expression [6], we ﬁrst deter-
mined the optimal doses of the following inhibitors in EGF treated
HEY ovarian carcinoma cells: PP2 (general Src family tyrosine ki-
nase (SFK) inhibitor, 10 lM), U0126 (MAPK inhibitor, 10 lM),
and PD153035 (EGFR and HER2/neu kinase inhibitor, 100 nM) (re-
sults not shown). With 25 lM As2O3 co-treated with PP2 (Fig. 2A–
C), we observed a marked reduction of SnoN, together with a slight
reduction in p-AKT compared to As2O3 alone or PP2 alone. Similar
results were obtained in cells treated with 10 lM As2O3 for 18 h
(Fig. 3F).
To determine if As2O3-induced changes in SnoN expression
are due to transcriptional upregulation, we co-treated HEY cells
with actinomycin D (transcriptional inhibitor) and As2O3
(Fig. 2D). With actinomycin D, induction of SnoN protein was
markedly reduced suggesting that SnoN levels induced by
As2O3 are due to transcriptional upregulation. To determine
whether Src tyrosine kinase mediates changes in SnoN mRNA
transcripts, we performed real-time PCR. We observed a 2.8-fold
increase in SnoN expression with As2O3, which was markedly re-
duced by PP2 (40% reduction, Fig. 2E). In contrast, U0126 did not
alter SnoN mRNA while PD153035 led only to only a slight
reduction in SnoN mRNA (results not shown). Inhibition of Src
kinase activity was validated via Western analyses for p-Src
(Y416) (Fig. 2B). Although the use of PP2 suggests that Src con-
tributes to transcriptional upregulation of SnoN with As2O3, this
could not be validated with SU6656 [9], another speciﬁc Src ki-
nase inhibitor (Fig. 2F). With this inhibitor, we did not observe
marked changes in SnoN or pAKT/pY-EGFR. SU6656 exhibits
higher speciﬁcity to speciﬁc Src family kinases relative to PP2;
thus, the differential response may be due to effective inhibition
of different Src family kinases by PP2 and SU6656 involved in
regulating the downstream effects of As2O3.
We next assessed whether As2O3-induced activation of Src
modulates expression of ShcA/Grb2 or the ability of EGFR to inter-
act with these adaptor proteins. Thus, we stimulated cells with
As2O3 (1 and 6 h) in the absence/presence of 10 lM PP2 and con-
trasted this response with EGF (5 min and 1 h). With both treat-
ment conditions, we observed a dramatic reduction in pY-EGFR
with PP2 treatment. As expected, the reduced mobility of p66 ShcA
isoform (phosphorylated form) observed with EGF treatment was
reduced in the presence of PP2 (Fig. 2G). Together, these results
suggest that activation of Src is necessary for phosphorylation of
EGFR in response to As2O3 (and EGF). To assess whether Src mod-
ulates the As2O3-induced interaction of EGFR with ShcA/Grb2, we
performed immunoprecipitation of EGFR in the presence/absence
of PP2 (Fig. 2H). With As2O3, PP2 reduces pY-EGFR and
co-immunoprecipitating p66 ShcA/Grb2. This contrasts with
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co-immunoprecipitated with EGFR (although increased mobility
was observed with only a subtle reduction in bound Grb2).
Collectively, these results indicate that upon As2O3 treatment, Src
activity contributes to EGFR tyrosine phosphorylation and its
interaction with downstream adaptor molecules (ShcA/Grb2) with
contrasting characteristics to that of EGF-mediated EGFR/Shc/Grb2
interactions.3.3. PI3K inhibitors alter As2O3-mediated SnoN expression and cell
survival
Since AKT was activated 1 h post As2O3 treatment prior to
changes in SnoN expression (see Fig. 1B), we next assessed
whether the PI3K pathway contributes to As2O3-mediated
increases in SnoN expression via the use of PI3K inhibitors
(LY294002 and GDC0941). With increasing doses of these
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analyses performed [n = 4]. (B) HEY cells were treated with PP2 (10 lM) only or for 2 h prior to stimulation with As2O3 (25 lM) for 6 h. Cells lysates were harvested and
Western analyses performed [n = 2]. (C) Densitometric analyses of SnoN (6 h) is shown for data presented in B. (D) HEY cells were treated with 25 lM As2O3 in the presence/
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either 1 or 6 h. Cell lysates were collected (‘‘inputs’’) andWestern analyses performed [n = 2]. (H) Using lysates presented in G, immunoprecipitation (IP) was performed using
anti-EGFR rabbit polyclonal antibody followed by Western analyses.
10 K.M. Kodigepalli et al. / FEBS Letters 587 (2013) 5–16inhibitors with 18 h As2O3, we observed a dramatic reduction in p-
AKT, SnoN, and XIAP, with a corresponding increase in cleaved
PARP and caspase 3/7 activity (Fig. 3A–D). The PI3K/AKT pathwaycould transcriptionally regulate SnoN as noted with a 50% reduc-
tion in mRNA transcripts upon co-treatment of As2O3 with
LY294002 (Fig. 3C). With 6 h 25lM As2O3 treatment, we observed
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with LY294002 (and to a lesser extent with GDC0941) (Fig. 3E).
Similar results were obtained with cells treated at 10 lM As2O3
for 18 h (Fig. 3F). We also targeted PIK3CA (catalytic subunit of
PI3K) with siRNA in combination with As2O3 and observed a
marked reduction in SnoN expression with 6 h As2O3 (Fig. 3G and
H). Co-treatment of LY294002 (or GDC0941, results not presented)
with As2O3 increased apoptosis as determined via annexin V stain-
ing (Fig. 3I–K). No dramatic changes were observed with LY294002
or GDC0941 treatments alone. Collectively, these results implicate
As2O3-induced activation of the PI3K/AKT pathway in altering
SnoN expression and cell survival.
3.4. siRNA targeting EGFR, MAPK1, and pp60 c-Src alter As2O3-
mediated cell survival
To further examine whether pp60 c-Src (one of the SFK family
members) may be involved in altering the As2O3-mediated cell
death response, we assessed the effect of siRNAs targeting this spe-
ciﬁc Src family member. Additionally, we examined the effect of
siRNAs against MAPK1 (targets p42 ERK1, shown to be sufﬁcient
for reducing tumor cell viability [10]) and EGFR (one of the proteins
tyrosine phosphorylated upon As2O3 treatment). In the presence of
As2O3 and EGFR or MAPK1 siRNA, we observed a marked reduction
in pY-EGFR (Fig. 4A). Further, we observed a marked reduction in
cleaved PARP with increased XIAP upon knockdown of MAPK1/
EGFR; in addition, we observed increased cleaved PARP with reduc-
tion in XIAP with pp60 c-Src siRNA relative to mock or non-target-
ing siRNA treated cells (Fig. 4A). These results suggest that
knockdown of MAPK1, EGFR, and pp60 c-Src leads to changes in cellviability via modulation of anti-apoptotic signaling mediators. In-
deed, the changes in cell viability for MAPK1 and pp60 c-Src siRNA
were conﬁrmed via Annexin V/PI staining (Fig. 4B). Although reduc-
tion of EGFR and MAPK themselves does not alter SnoN expression,
there was also no change with pp60 c-Src knockdown which con-
trasts with the PP2 results but supports the SU6656 inhibitor stud-
ies. The absence of SnoN changes with pp60 c-Src siRNA suggests
that othermembers of the Src tyrosine kinase family (of whichmul-
tiple members exist including Yes, Lyn, or Fyn) may be responsible
for the changes in SnoN expression. The EGFR and MAPK pathway
appear to be disconnected to the regulation of SnoN expression.
Since reduced p66 ShcA isoform is associated with increased
survival [11], we next assessed whether p66 ShcA could be in-
volved in regulating As2O3-mediated increased interaction be-
tween EGFR with Grb2. We immunoprecipitated EGFR in cells
treated with non-targeting or p66 ShcA siRNA in the presence/ab-
sence of As2O3. The p66 ShcA siRNA, designed to target the CH2
homology domain, is speciﬁc to p66 (not p46/p52) (Fig. 4C). Upon
As2O3 (and EGF) treatment, we noted a subtle but reproducible
reduction in pY-EGFR with p66 siRNA in EGFR immunoprecipitates
(Fig. 4D). Although interaction of p52 ShcA with EGFR was not dis-
rupted, the abundance of Grb2 with EGFR was markedly reduced
following p66 ShcA knockdown with As2O3. Together, these results
suggest that p66 ShcA is required for the interaction of Grb2 with
EGFR upon As2O3 treatment.
4. Discussion
We previously demonstrated that As2O3 induces autophagy in
ovarian carcinoma cells and that increased expression of SnoN, a
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K.M. Kodigepalli et al. / FEBS Letters 587 (2013) 5–16 13TGFb co-transcriptional repressor, modulates As2O3-induced pro-
tective autophagy [6]. Since EGFR and downstream signaling path-
ways (PI3K/AKT) are ampliﬁed and/or dysregulated in cancers
[3,12,13], we assessed their contribution to As2O3-induced cell
death response and to regulation of SnoN expression in ovarian
cancer cells. Since HEY cells are very resistant to As2O3, we as-
sessed three independent doses of As2O3 (5, 10, and 25 lM) which
elicit similar expression proﬁles of the assessed markers; however,
we noted increased intensity of cleaved PARP and cell death with
higher doses of As2O3 (cleaved PARP together with reduction in
anti-apoptotic markers (i.e. Bcl-XL and XIAP) is observed weakly
with 10 lM As2O3). In A431 cells, a dose of 20 lM As2O3 was uti-
lized to investigate the cellular response on the EGFR/ERK signaling
cascade [14,15]; this dose is markedly higher to doses used in thetreatment of APL (2 lM As2O3). As2O3-treated ovarian carcinoma
cells show a rapid and transient AKT activation prior to pY-EGFR.
We now demonstrate that the PI3K pathway transcriptionally reg-
ulates SnoN expression and the consequent cell death response
(apoptosis) via the use of PI3K inhibitors (LY294002/GDC0941)
and speciﬁc siRNA targeting PIK3CA (Figs. 3G and 4E). These re-
sponses are similar to TG-interacting factor (TGIF), another tran-
scriptional TGFb co-repressor, whose expression levels are
increased post-transcriptionally as a result of activation of the
PI3K/AKT pathway in HepG2 cells in response to As2O3 [16].
We observed that Src activity increased upon treatment with
As2O3 (5, 10 and 25 lM) eliciting a biphasic proﬁle (early (1–6 h)
and late response (18 h)). We propose that the initial activation
may be responsible for the early cytoprotective response while
I 
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14 K.M. Kodigepalli et al. / FEBS Letters 587 (2013) 5–16the later activation may be involved in eliciting the cell death re-
sponse. Indeed, Src family members have been described to elicit
both functionalities (pro- and anti-apoptotic responses) which
may depend on the involvement of different Src family members
[17]. The fate of the cell will likely depend, however, on the overall
balance of survival and death inducing signals. Cell treatments per-
formed in the presence of PP2 could markedly reduce SnoN mRNA
and protein. In contrast, SU6656 and siRNA targeting pp60 c-Src
did not alter SnoN levels (or pY-EGFR/p-AKT). Since this differential
response may be due to effective inhibition of different Src family
kinases by PP2 and SU6656, future directions would include iden-
tiﬁcation of the speciﬁc Src family kinase member that was acti-
vated upon As2O3 treatment which modulates SnoN expression.
Since phosphatase activity was not altered markedly with As2O3
treatment in our cells, other mechanisms leading to EGFR activa-
tion may include Src activity which is inﬂuenced by reactive oxy-
gen species (ROS) generated with As2O3 [18]. Interestingly, SnoN
induction following As2O3 treatment could be reverted by co-treat-
ment with an anti-oxidant, N-acetyl-L-cysteine (NAC) [6]. Thus, in
response to As2O3, Src activity may be upregulated via ROS leading
to increased SnoN levels. It has been reported that activation of Src
leads to transactivation of the EGF receptor; in response to As2O3,
EGFR can be phosphorylated at Y845 and Y1173, which arewell-established c-Src phosphorylation sites [15]. In our studies,
we observed that the kinetics of EGFR/p66 ShcA activation and
interaction with Grb2 upon As2O3 treatment was markedly slower
relative to EGF and further, was modulated differently in response
to PP2 and p66 ShcA siRNA. Thus, in contrast to EGF treatment, a
ligand-independent mechanism (i.e. activation of non-receptor
Src tyrosine kinases) is likely to be involved under our conditions
leading to receptor activation in cells treated with As2O3 [19].
Interestingly, activation of EGFR signaling cascade can also
counteract the cell death response to various chemotherapeutic
agents such as cisplatin [20]. These results could be explained by
the level of stress induced; under moderate oxidative stress condi-
tions, pY-EGFR elicits a pro-survival role while under severe oxida-
tive stress, pY-EGFR leads to increased cell death [21,22]. Although
knockdown of EGFR and MAPK1 did not alter SnoN levels, they in-
creased cell survival. Indeed, siRNA towards MAPK1 is similar to
that reported to ERK1/ERK2 which suppresses cell viability in ovar-
ian cancer cells with chemotherapeutic agents [10]. However, in
contrast to cisplatin treatment where disruption of EGFR activation
increases cell death [23], disruption of EGFR/MAPK signaling with
As2O3 in our system leads to increased cell survival with recovery
of XIAP expression. Indeed, As2O3 can induce apoptosis by prevent-
ing induction of XIAP and Bcl-XL [24] together with induction of
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K.M. Kodigepalli et al. / FEBS Letters 587 (2013) 5–16 15Noxa and Bim [25]. The EGFR and MAPK pathway appears to be
disconnected to the regulation of SnoN expression. The
cytoprotective pathway may involve an early burst of Src activity
leading to SnoN upregulation which is eventually overcome by
the strength of the pro-death EGFR/Src (late burst of activity)/
MAPK pathway.Since the catalytic subunit of PI3K (PIK3CA) is located at 3q26.2,
upstream of the chromosomal location of SnoN at 3q26.2, we pro-
pose that oncogenic cooperativity may occur between PI3K and
SnoN in ovarian cancer chemoresponsiveness. Collectively, our re-
sults implicate the cytoprotective Src/PI3K pathway as contribut-
ing to SnoN expression; this may be a valuable pathway to target
16 K.M. Kodigepalli et al. / FEBS Letters 587 (2013) 5–16or develop new strategies for increasing the therapeutic effective-
ness of As2O3 and other chemotherapeutic agents for treatment of
cancer patients.
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